S

Syncom Formulations (India) Ltd
NSE:SYNCOMF

Watchlist Manager
Syncom Formulations (India) Ltd
NSE:SYNCOMF
Watchlist
Price: 13.05 INR -3.69%
Market Cap: 12.3B INR

Relative Value

The Relative Value of one SYNCOMF stock under the Base Case scenario is hidden INR. Compared to the current market price of 13.05 INR, Syncom Formulations (India) Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SYNCOMF Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
70
vs Industry
28
Median 3Y
3.4
Median 5Y
3.4
Industry
2.7
vs History
70
vs Industry
9
Median 3Y
32.5
Median 5Y
31.9
Industry
21.6
vs History
25
vs Industry
Median 3Y
-376.2
Median 5Y
-382.8
Industry
16.9
vs History
vs Industry
Median 3Y
-41.4
Median 5Y
-44.1
Industry
22.9
vs History
62
vs Industry
15
Median 3Y
4.5
Median 5Y
4.4
Industry
2.3
vs History
70
vs Industry
29
Median 3Y
3.3
Median 5Y
3.3
Industry
3
vs History
70
vs Industry
19
Median 3Y
9.5
Median 5Y
9.4
Industry
5.6
vs History
70
vs Industry
10
Median 3Y
27.7
Median 5Y
27.1
Industry
13.4
vs History
70
vs Industry
10
Median 3Y
30.9
Median 5Y
30
Industry
16.7
vs History
25
vs Industry
Median 3Y
-360
Median 5Y
-366.7
Industry
16.1
vs History
25
vs Industry
Median 3Y
-200.9
Median 5Y
-204.6
Industry
18.9
vs History
60
vs Industry
14
Median 3Y
4.8
Median 5Y
4.7
Industry
2

Multiples Across Competitors

SYNCOMF Competitors Multiples
Syncom Formulations (India) Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Syncom Formulations (India) Ltd
NSE:SYNCOMF
12.7B INR 2.5 21.3 19.6 21.5
US
Eli Lilly and Co
NYSE:LLY
977B USD 16.4 53.1 35.6 38.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
528.3B USD 5.7 21 17.2 22.3
CH
Roche Holding AG
SIX:ROG
275.3B CHF 4.5 29.2 12.4 14.5
UK
AstraZeneca PLC
LSE:AZN
217.5B GBP 5 31 108.3 158.5
CH
Novartis AG
SIX:NOVN
219.7B CHF 4.9 19 12 15.5
US
Merck & Co Inc
NYSE:MRK
276B USD 4.3 14.5 10.3 12.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 15.6 10.9 12.6
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
147.2B USD 2.3 15 7.6 10.4
P/E Multiple
Earnings Growth PEG
IN
S
Syncom Formulations (India) Ltd
NSE:SYNCOMF
Average P/E: 24.4
21.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.1
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
21
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.2
29%
1
UK
AstraZeneca PLC
LSE:AZN
31
37%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.5
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
15.6
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
27%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
S
Syncom Formulations (India) Ltd
NSE:SYNCOMF
Average EV/EBITDA: 401.7
19.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.6
34%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
17.2
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
12
6%
2
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
S
Syncom Formulations (India) Ltd
NSE:SYNCOMF
Average EV/EBIT: 1 714.3
21.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.2
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
22.3
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
158.5
23%
6.9
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
7%
1.5